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Abstract
Gene augmentation is an attractive and viable approach in treatment of inherited diseases, despite its limitations, such as the eliciting of
host immune response, and the sustainability of gene expression. Therefore, alternative therapeutic approaches are being investigated, such as
the use of chimeric RNA–DNA oligonucleotides (chimeraplasts), in which a mutated allele that already exists in an affected individual can
be corrected. Although the only gene defects that can be corrected by chimeraplasty are point mutations, and the correction frequencies are
variable, it has been observed that intracellular delivery of oligonucleotides is likely to be more efficient than that of plasmid DNA or viral
vectors. Furthermore, corrected genes are expressed from their autologous promoters, thus ensuring correct spatial and temporal expression.
Here we report on the recent progress made in the field of chimeraplasty, and the problems encountered. D 2002 Elsevier Science B.V. All
rights reserved.
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1. Introduction
The conventional approach to the treatment of inherited
disease by gene therapy is that of gene augmentation. That
is, the supply, in trans, of a functional copy of the gene
which is defective in the diseased state. This is mostly
achieved by the introduction of functional cDNAs or, if the
gene is short enough, genomic DNA sequences, into plas-
mid or viral vectors. The viruses that are in widespread use
in gene delivery research include adeno-associated viruses
(AAV), retroviruses (RV), lentiviruses such as HIV, SIV and
EIAV, and most commonly, adenoviruses (Ad). Each virus
family has distinct advantages over others, but they also
have their drawbacks. For example, Ad has the ability to
infect quiescent, or nondividing cells. This makes it a far
more attractive tool for engineering skeletal muscle cells
than RV, for example, which can only infect dividing cells.
However, RV have the advantage over Ad of being able to
insert the therapeutic transgene into the host genome, which
often results in more sustainable levels of expression.
Due to their often pathogenic nature, it is important that
the viral vectors are used simply as delivery vehicles, and
that they only perform one transduction event. This is
achieved by deleting large amounts of the viral genome,
ensuring that the subsequent viruses are ‘‘replication defec-
tive’’. This has the added advantage of creating more space
in the genome to insert foreign (i.e. therapeutic) DNA. A
major drawback of many viruses is the limited amount of
nucleic acid that can be successfully packaged into infec-
tious virus particles, so large cDNAs, for example dystro-
phin, cannot be inserted in their complete state, and efforts
have to be made to establish which, if any, regions of the
coding sequence may be deleted while still generating a
functional protein.
Even when a complete gene delivery system has been
generated, problems are encountered when its therapeutic
benefit is assessed in vivo. Most viruses, even though
replication defective, will still elicit a host immune response,
whether cell-mediated or humoral. Furthermore, in cases of
inherited disease in which a protein is completely absent in
the diseased state, the introduction of a therapeutic copy of
that gene is itself likely to induce an immune response,
which is clearly undesirable, and will result in no therapeutic
benefit whatsoever. If the chosen viral vector does not
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integrate its genome into that of the host, there is likely to be
a severely reduced longevity of expression, especially in
rapidly dividing cells, but if integration does occur, there are
serious risks associated with insertional mutagenic effects on
the host genome. Moreover, if all of these problems can be
overcome, there is the potential for heterologous promoters
to be down-regulated within a short space of time, leading to
a loss of therapeutic gene expression.
Not all of the above problems are insurmountable, and the
use of gene augmentation remains an attractive and viable
option as a potential therapy for inherited disease. However,
the search for alternative approaches to genetic medicine has
continued, and within the past 5 years, a new technique has
been developed that has the potential to overcome the
majority of the problems associated with gene augmentation.
Chimeric RNA–DNA oligonucleotides (now termed chi-
meraplasts) that are directed to a particular sequence in a
gene have been shown to be able to bring about site-specific
point mutations within that sequence (Table 1). If such a
point mutation had the effect of reversing a mutation that
causes a genetic disease, this method of gene correction
could be used as a genetic medicine, and would have a
number of distinct advantages over gene therapy as achieved
by gene augmentation.
For example, there is no restriction to the size of the gene
that can be corrected. So in cases of Duchenne Muscular
Dystrophy, there is the clear potential for point mutations
that disrupt the reading frame of the dystrophin gene to be
corrected, whereas delivery of the complete cDNA cannot
easily be achieved using viral vectors. Moreover, there is no
risk of the generation of replication-competent pathogens, as
is potentially the case when engineering virus backbones.
The risks associated with insertional mutagenesis by certain
viral vectors that integrate at random sites in the genome are
also overcome completely. Perhaps the most important of all
the advantages that chimeraplast-mediated gene correction
has over gene augmentation is that the corrected gene is
expressed using its autologous promoter, to an appropriate
level in a spatially and temporally relevant manner. The
principal barrier to the efficacy of the chimeraplasty method
is that the only defects that can be corrected are substitutions
and single base insertions or deletions.
The use of chimeraplasts to induce and correct point
mutations was first described in 1996 by Eric Kmiec and co-
workers, then at Thomas Jefferson University in Philadel-
phia, PA, USA [1]. In this landmark study, chimeraplasts
were used to correct a nonfunctional allele of a human
alkaline phosphatase gene on an expression plasmid in
Chinese hamster ovary (CHO) cells. The rate of correction
was demonstrated to be in the order of 30% to 40%, by
histochemical staining for the presence of functional alka-
line phosphatase, by an allele-specific hybridisation techni-
que, and by direct sequencing of polymerase chain reaction
(PCR) products.
The first demonstration of the technique in a genomic
context also came from Kmiec’s lab [2]. Chimeraplasts were
designed to correct the sickle cell anemia mutation (hS) in
h-globin to the wild-type (hA) allele. When introduced to
lymphoblastoid cell lines that were homozygous for the hS
allele, correction to hAwas observed at a detectable level, as
adjudged by genomic Southern hybridisation, PCR-RFLP
and direct sequencing of PCR products. Importantly, this
was achieved in the absence of any significant increase in
random mutations, demonstrating the safety of the technique
as a potential genetic medicine. Shortly afterwards, the
correction of an alkaline phosphatase gene in a genomic
context was performed, with an intracellular correction
efficiency in excess of 40% [3].
The next significant advancement in the method came
the following year, with the first demonstration of the
success of chimeraplasty in a whole animal. Chimeraplasts
designed to induce a Hemophilia B-causing mutation into
the clotting factor IX gene were introduced into rat models
by tail–vein injection. Conversion of the wild-type to the
mutant allele was observed at levels of up to 40%, following
administration of two doses of chimeraplast. A single dose
using less oligonucleotide yielded a correction frequency of
about 11% [4].
Table 1
Examples of the widespread use and potential of chimeraplasty
Gene Syndrome System used Conversion rate
quoted (%)
Chimeraplast designa Reference
Alkaline phosphatase CHO cells 30 68mer (10–5–10) [1]
hs globin Sickle cell anaemia Lymphoblastoid cells 68mer (10–5–10) [2]
Alkaline phosphatase Hepatoma cells 11 68mer (10–5–10) [3]
Factor IX Haemophilia B Rat, in vivo 40 68mer (10–5–10) [4]
Kanamycin-resistance Cell-free extract 0.1 68mer (10–5–10) [14]
UGT1A1 Crigler–Najjar syndrome Gunn rat, in vivo 20 76mer (10–9–10) [5]
Acetolactate synthase Herbicide resistance Tobacco 68mer (10–5–10) [10]
Maize 68mer (10–5–10) [11]
Tyrosinase Albinism Mouse, in vivo 68mer (10–5–10) [6]
Dystrophin DMD mdx mouse, in vivo 20 78mer (12–6–12) [7]
GRMD dog, in vivo 74mer (10–5–13) [8]
Apolipoprotein E Atherosclerosis CHO cells 35 68mer (10–5–10) [20]
a The total length of the oligonucleotide and the composition, in numbers of nucleotides, of the chimeric strand (RNA–DNA–RNA).
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It is evident from this and other studies that the liver is
particularly amenable to the uptake of chimeraplasts [4,5],
but other organs, including skin [6] and muscle [7,8], are also
well suited as targets for the technique, and can result in
potentially therapeutic levels of correction, approaching 20%
in the dystrophin-deficient mdx mouse [7]. Liver targetting
has been further enhanced by the use of galactosylated
delivery agents such as PEI, which bind to the asialoglyco-
protein receptor on the surface of hepatocytes [9].
The technique has also been demonstrated in plants,
showing the potential to introduce herbicide resistance into
tobacco [10] and maize [11,12], by modification of the ace-
tolactate synthase (acetohydroxyacid synthase) gene. While
this correction has been observed only at very low levels,
the application of chimeraplasty to genetic modification in
this way may overcome many of the problems associated
with the introduction of exogenous genes into random sites
in the plant genome. As a result, the technique may become
of enormous agronomic benefit.
The methods used in the analysis of chimeraplast-medi-
ated correction have rightly been the focus of much scrutiny,
to ascertain that the results that have been quoted have not
been biased in favour of higher apparent correction frequen-
cies. For example, an early criticism of PCR-based evidence
was that a long-lived chimeraplast might itself act as a pri-
mer and, as it contains the ‘‘corrected’’ sequence, skew the
result towards high correction efficiency [13]. However, this
has been discounted by corroborative PCR-independent
Fig. 1. (A) The structure of a typical chimeraplast, in which the chimeric (targeting) strand is entirely base-paired to the all-DNA (correcting) strand. (B)
Schematic representation of chimeraplast action. Strand invasion by the chimeraplast is initiated by RecA, and stabilised by base pairing of the targeting strand
to the upper strand of the genomic DNA. The base pairing of the correcting strand to the lower strand of the genomic DNA creates a mismatch, which is
repaired. This example depicts a T to C mutation.
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techniques, including Southern blots of genomic DNA,
protein analyses and functional biochemical assays. More-
over, the emergence of real-time PCR as a routinely avail-
able technique will also counteract the aforementioned
argument.
2. Chimeraplast design
The design of the chimeraplast used in the first experi-
ments [1] has remained largely unchanged to the present day.
It consists of 68 nucleotides (nt) that base-pair to give a
double-stranded molecule, in which one strand is comprised
entirely of DNA, and the other strand comprises of two runs
of 10 nt of 2V-O-methyl (2V-O-Me) RNA, separated by a 5 nt
stretch of DNA (Fig. 1A). A short region predicted to have a
high melting temperature (a GC clamp) is located at the 3V
end, and four T residues separate the double-stranded
regions, allowing the energetically favourable formation of
tight hairpins. The base that is to be mutated lies at the centre
of the stretch of five DNA nucleotides on the chimeric
strand, and has its complement at the centre of the all-
DNA strand. This ensures that the chimeraplast is capable
of intramolecular base pairing along its entire length.
More recently, attempts have been made to study empiri-
cally the structure and efficiency of action of a chimeraplast
[14,15]. A large number of molecules were tested, all of
which were designed to correct an inactivating mutant in a
bacterial kanamycin-resistance gene in a cell-free extract.
Following incubation with the chimeraplast, the plasmids
were transformed into Escherichia coli cells. In this way, an
accurate estimate of the efficiency of the correction was
determined by an analysis of the number of kanamycin-
resistant colonies. The observations reported in these studies
suggest that changes can be made to the first generation
chimeraplast in order to improve its performance. For
example, if the targeting strand is made up entirely of 2V-
O-Me RNA, rather than being interspersed with a stretch of
DNA, the efficiency is increased by about 40%. This
enhancement in activity may be improved further by having
a mismatch between the genome and only the correcting (all
DNA) strand. That is, the 2V-O-Me RNA strand is entirely
complementary to the genome, and there is a mismatch
between the two strands of the chimeraplast. While this
would reduce the intramolecular melting temperature, the
melting temperature of the targeting strand to the genome
would be increased.
3. Mechanism of action
The improvements made to the structure described above
have implications for the mechanism of chimeraplast action
(Fig. 1B). It is presumed that invasion of the host genome is
initiated and stabilised by the chimeric strand; the Tm of a
hybrid between DNA and 2’-O-Me RNA is higher than that
of either DNA–DNA or DNA–RNA, and will thus be more
stable. Indeed, if the chimeric strand is replaced by one that
is comprised entirely of DNA, the ability of the oligonu-
cleotide to induce gene correction is reduced by a factor of
2, compared to the ‘‘classical’’ design [15]. Following base
pairing of the chimeric strand to the genomic target, the
DNA strand is then able to base-pair with the complemen-
tary strand. Whether this occurs solely by Watson–Crick
base pairing, or involves an element of Hoogsteen base
pairing is not clear. If Watson–Crick base pairs are used
exclusively, there is clearly no prospect for the chimeraplast
to bind both intra- and intermolecularly. Following the
invasion of the genome by the chimeraplast, the point
mutation in the genomic DNA that is mismatched with the
central base on the all DNA strand of the chimeraplast is
corrected. It was originally thought that both strands of a
first-generation chimeraplast could induce mutations, but
analyses of structural variants have shown this not to be the
case. Indeed, if only the chimeric strand is mismatched with
the genomic DNA, the conversion frequency is reduced by
95%, compared to a chimeraplast that has mismatches on
both strands.
It is not altogether clear as to the mechanism by which
the invasion and correction occurs, but recent evidence
suggests that the initial invasion is mediated by RecA and
its mammalian homologues. RecA is unable to catalyse the
invasion of duplex DNA by single-stranded oligonucleoti-
des, but if the complement of the oligonucleotide is also
included in the reaction, a displacement loop (D-loop) is
formed that is stable following the dissociation of RecA
[16]. It is proposed that chimeraplasts are able to form a
‘‘complement-stabilised’’ D-loop, and that the mismatch
that exists between the chimeraplast and the genome, along
with the recognition of the unusual four-stranded structure,
leads to repair of the region [15]. The actual mechanism of
mismatch repair is not well understood, but presumably
proceeds via excision of a region of the genome in the
vicinity of the mismatch and the D-loop, followed by DNA
replication by DNA polymerase y, using the all-DNA strand
of the chimeraplast as a template. The process is dependent
on a number of proteins, including MSH2, and is much more
efficient than homologous recombination. The dependence
of MSH2 in chimeraplasty has been demonstrated in cell-
free extracts, but the role of DNA polymerase y remains
unclear due to the lack of effect of its inhibitor aphidicolin
[14], and the repair may have been completed following
introduction of the treated plasmid into E. coli.
It is possible that the model systems that have been used
to assess the efficiency and mechanism of chimeraplast
activity are dependent on plasmid (i.e. supercoiled) DNA
for activity, and that the mechanism by which gene correc-
tion by chimeraplasts occurs in the mammalian genome is
somewhat different. Whether or not that is true remains to
be seen, but there is clear evidence from an increasing
number of studies that chimeraplasts can be effective in
mammalian cell cultures and whole animal models.
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Recent studies have also examined the mechanism by
which a single-stranded oligonucleotide might achieve gene
correction. It is apparent, from the use of model systems
such as those described above to test chimeraplasts, that
single-stranded oligonucleotides that correspond to the all
DNA (correcting) strand of a chimeraplast are able to
achieve conversion frequencies similar to the intact chimer-
aplast [17,18]. Conversely, oligonucleotides conforming
only to the chimeric (targeting) strand are incapable of
directing correction. The mechanism of strand invasion,
the first step of DNA repair systems, is likely to be different,
as is the intermediate structure in the process, given that
RecA cannot catalyse the invasion of a single-stranded
oligonucleotide into duplex DNA unless this occurs at one
end of the duplex, or if the duplex is in the form of
supercoiled DNA. Furthermore, extracts made from eukary-
otic cells with mutations in the MSH pathway have dem-
onstrated the lack of dependence on MSH2 or MSH3 for
correction by single-stranded oligonucleotides, and presum-
ably the whole mismatch pathway, in stark contrast to the
action of chimeraplasts [15,17]. However, the advent of
single-stranded oligonucleotides as alternatives to the tradi-
tional chimeraplast is a very important advance in the field
of targeted gene correction. A major contributor to the
variability of success with chimeraplasts has been the
difficulty in synthesis and purification of the reagents (see
below). These relatively short DNA oligonucleotides con-
taining fewer modifications are much easier to synthesise
and purify in large quantities than chimeraplasts, and are
considerably less costly, so are likely to be more attractive
should the technique become approved for clinical use.
Recent criticism has been levelled at the chimeraplast
technique in three areas [19]. First, that the technique is
somewhat variable. Reported correction efficiencies have
varied from 0.1% in cell-free extracts to as much as 40% in
whole animal models of human disease. It is not clear at this
stage what are the factors that contribute to this variability,
but one inconsistency between groups could be the quality
of the chimeraplast reagents themselves. However, work in
our laboratory has shown both very high efficiency, in the
case of the conversion of apolipoprotein E single nucleotide
polymorphisms (SNPs) in CHO cells [20], and in the case of
the introduction of certain atheroprotective genotypes of
Apolipoprotein AI, while others appear more refractory
[21]. All of the reagents used in these studies were manu-
factured by the same supplier (MWG Biotech, Ebersberg,
Germany), and while they appear to be of equivalent purity
and integrity, suggesting that there are some sites that are
more amenable to correction than others, it is possible that
minor differences between batches of chimeraplast could
contribute to this variation, and needs to be addressed
further. It might be proposed that GC content (which would
have an influence on the stability of chimeraplast-genome
hybrids) is key. This may be the case, since work in our
laboratory has shown high levels of correction in contexts
that have a high GC content [20,21], but a direct correlation
has yet to be established. There is also an apparent hierarchy
of the correction efficiencies achieved with different mis-
matches, with, for example, G to C changes being more
efficient than A to T [15].
Second, the likelihood of undesired mutations being
generated by the nonspecific interaction of the chimeraplast
with the genome has not been addressed in great detail. A
sequence of 25 nucleotides would be expected to occur at
random every 1015 base pairs, or approximately once in
375,000 human genomes. Thus, a standard chimeraplast
with a 25 base pair homology to the genome would be
expected to interact only with the specified sequence.
Clearly, if the region of homology is reduced substantially,
the probability of nonspecific effects will be higher. Two
pieces of work have given some indication of the potential
risk involved. Chimeraplasts that were designed to test the
role of the chimeric (RNA–DNA) strand, and which are
able to direct only very low levels of correction of a ka-
namycin-resistance gene, were shown to introduce non-
complementary mutations into the gene, but at the correct
site [15]. Moreover, sequencing of an entire 10 kb plasmid
containing the targeted kanamycin-resistance gene, follow-
ing chimeraplast treatment, has demonstrated that the only
mutation was at the correct position (M. Blaese, personal
communication).
The third area of criticism is concerned with the low
number of published studies that have originated from
independent laboratories [19]. While it is true that the
majority of studies have come from the laboratories of
Kmiec and Steer, it is evident that there is increasing success
by other groups. For example, the work on ApoE [20] and
ApoAI [21] SNPs has been performed entirely independ-
ently of those two laboratories, and we would endorse the
suggestion that a network be set up [19,21], allowing the
frank and free exchange of results and concerns.
4. Conclusions
It is evident that the use of chimeraplasts and single-
stranded oligonucleotides to achieve genetic correction at
pathologically significant loci is still a technique of enor-
mous promise, and one which will be of benefit in cases of
disease that cannot be effectively managed by conventional
gene augmentation therapy. The advances made in the past
year in the understanding of the mechanisms and pathways
by which correction is brought about will increase our
knowledge of the method, which will inevitably lead to
overcoming the problems that have become apparent in the
5 years since its inception. The question of whether it will
become a widespread method of combating inherited dis-
ease remains unanswered. There are clearly organs, such as
the liver, which are more amenable to its use than others.
This may limit the applicability of the technique, but as the
controversial issues surrounding it are discussed openly, the
mythology will inevitably be replaced by facts that will
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allow chimeraplasts and single-stranded oligonucleotides to
reach their true potential.
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